



Published in final edited form as:

*J Low Genit Tract Dis.* 2019 April ; 23(2): 151–160. doi:10.1097/LGT.0000000000000462.

## The Clinical Role of LASER for Vulvar and Vaginal Treatments in Gynaecology and Female Urology: a Best Practice Document

Mario Preti, MD<sup>1</sup>, Pedro Vieira-Baptista, MD<sup>2,3</sup>, Giuseppe Alessandro Digesu, PhD<sup>4</sup>, Carol Emi Bretschneider, MD<sup>5</sup>, Margot Damaser, PhD<sup>5,6,7</sup>, Oktay Demirkesen, MD<sup>8</sup>, Debra S. Heller, MD<sup>9</sup>, Naside Mangir, MD<sup>10,11</sup>, Claudia Marchitelli, MD<sup>12</sup>, Sherif Mourad, MD<sup>13</sup>, Micheline Moyal-Barracco, MD<sup>14</sup>, Sol Peremateu, MD<sup>12</sup>, Visha Tailor, MD<sup>4</sup>, Tufan Tarcan, MD<sup>15</sup>, J.B De Elise, MD<sup>16</sup>, and Colleen K. Stockdale, MD, MS<sup>17</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, University of Torino, Torino, Italy

<sup>2</sup>Hospital Lusíadas Porto, Porto, Portugal

<sup>3</sup>Lower Genital Tract Unit, Centro Hospitalar de São João, Porto, Portugal

<sup>4</sup>Imperial College Healthcare, Department of Urogynaecology, London, UK

<sup>5</sup>Center for Urogynecology & Pelvic Reconstructive Surgery, Obstetrics, Gynecology & Women's Health Institute, Cleveland Clinic, Cleveland, OH, USA

<sup>6</sup>Glickman Urological and Kidney Institute and Department of Biomedical Engineering Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

<sup>7</sup>Advanced Platform Technology Center Louis Stokes Cleveland VA Medical Center Cleveland, OH, USA

<sup>8</sup>Istanbul University Cerrahpa a Faculty of Medicine, Department of Urology, Istanbul, Turkey

<sup>9</sup>Department of Pathology & Laboratory Medicine, Rutgers-New Jersey Medical School, Newark, NJ, USA

<sup>10</sup>Kroto Research Institute, Department of Material Science and Engineering, University of Sheffield, UK.

<sup>11</sup>Royal Hallamshire Hospital, Department of Urology, Sheffield, UK

<sup>12</sup>Department of Gynecology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

<sup>13</sup>Ain Shams University, Department of Urology, Cairo, Egypt

<sup>14</sup>Department of Dermatology, Hôpital Tarnier-Cochin, Paris, France

<sup>15</sup>Marmara University School of Medicine, Department of Urology, Istanbul, Turkey.

---

**Corresponding author:** Pedro Vieira Baptista, Hospital Lusíadas Porto, Porto, Portugal, Secretary.general@issvd.org, +351 917718495.

No funds were received for the elaboration of this paper

IRB status: this paper was considered IRB exempt

No conflicts of interest to declare

<sup>16</sup>Department of Urology, Massachusetts General Hospital - Harvard Medical School Boston, MA, USA

<sup>17</sup>Department of Obstetrics & Gynecology, University of Iowa, Iowa City, IA, USA

## Abstract

In this best practice document, we propose recommendations for the use of LASER for gynaecologic and urologic conditions such as vulvovaginal atrophy, urinary incontinence, vulvodynia and lichen sclerosus based on a thorough literature review. Most of the available studies are limited by their design; for example they lack a control group, patients are not randomized, follow up is short term, series are small, LASER is not compared with standard treatments, and most studies are industry sponsored. Due to these limitations, the level of evidence for the use of LASER in the treatment of these conditions remains low and does not allow for definitive recommendations for its use in routine clinical practice.

Histological evidence is commonly reported as proof of tissue regeneration following LASER treatment. However, the histological changes noted can also be consistent with reparative changes after a thermal injury rather than necessarily representing regeneration or restoration of function.

The use of LASER in women with vulvodynia or lichen sclerosus should not be recommended in routine clinical practice. There is no biological plausibility or safety data on its use on this population of women.

The available clinical studies do not present convincing data regarding the efficacy of LASER for the treatment of vaginal atrophy or urinary incontinence. Also, while short-term complications seem to be uncommon, data concerning long-term outcomes are lacking.

Therefore, at this point, LASER is not recommended for routine treatment of the aforementioned conditions unless part of well-designed clinical trials or with special arrangements for clinical governance, consent and audit.

## Précis:

The Clinical Role of LASER for Vulvar and Vaginal Treatments in Gynaecology and Female Urology.

## Keywords

LASER; genitourinary syndrome of menopause; urinary incontinence; vulvovaginal atrophy; vaginal laxity; lichen sclerosus; ISSVD; ICS

## Introduction

“Light Amplification by Stimulated Emission of Radiation” (LASER) has been widely used in gynecology and urology for more than 40 years. It is well established in the management of HPV-related genital lesions, prostate vaporization, and lithotripsy <sup>1,2</sup>. More recently the use of trans-vaginal or vulvar LASER has escalated to be used as a panacea for several

urological and gynecological conditions, such as: lichen sclerosus, vulvodynia, “vaginal laxity”, overactive bladder and pelvic organ prolapse.

Limited ex-vivo studies have suggested that LASER has the potential to modify tissue characteristics. Clinically it has already been adopted for tissue remodelling of non-mucosal scars and wrinkles with relative success. These findings have led to the concept that LASER technology could be used in the treatment of vaginal atrophy<sup>3</sup> and has already been utilised and marketed as a ‘treatment’ or therapy for vaginal “rejuvenation” and “Designer LASER Vaginoplasty” by the aesthetics industry.

Several published studies have suggested that fractional microablative CO<sub>2</sub> and Er:Yag LASER effectively treat not only atrophic vaginal mucosa (2014)<sup>3</sup>, but also improve urinary incontinence (2015)<sup>4</sup>. From the initial studies, the jump to aggressive marketing and widespread adoption of the LASER technology was quick. However, the studies failed to provide definitive evidence of its safety and effectiveness. Flaws of these studies include short follow-up time, absence of control groups, lack of standardized outcome measures, and the involvement of industry sponsorship.

Vaginal atrophy related to hypoestrogenism is recognized as a prevalent and significant cause of morbidity in the postmenopausal population<sup>5</sup>. In 2014 it was integrated into the broader definition of “genitourinary syndrome of menopause” (GSM)<sup>6</sup>. GSM classifies an extensive list of signs and symptoms common to the natural process of female menopause as a syndrome. This umbrella term also carries the risk of classifying true disease (i.e. lichen sclerosus) as GSM<sup>7</sup>.

Despite the lack of a true functional or anatomical definition, the use of the term “vaginal laxity” has become more widespread<sup>8</sup>. The term has been defined by the International Urogynaecological Association (IUGA) and the International Continence Society as a feeling of vaginal looseness<sup>9</sup>, a woman’s subjective sensation of vaginal “looseness”. “Vaginal rejuvenation” with LASER is targeted to women with ‘vaginal laxity’ as a procedure to improve the sensation of laxity and thus enhance sexual function in those with decreased vaginal sensation<sup>10</sup>.

In 2007 the American College of Obstetrics and Gynecology (ACOG) included “vaginal rejuvenation” and “designer vaginoplasty” in a list of procedures that were “not medically indicated” due to a “lack of evidence confirming safety and effectiveness”<sup>11</sup>. However the US Food and Drug Administration (FDA) licenced the CO<sub>2</sub> LASER systems for “incision, excision, ablation, vaporization and coagulation of body soft tissues and was used by specialities such as aesthetics (...), otolaryngology (...), gynecology, neurosurgery and genitourinary surgery” in 2010<sup>12</sup>. Other LASER manufacturers requested FDA approval in 2014, with similar licence terms approved<sup>13</sup>. Er:YAG LASERs were licensed for dermatologic uses: coagulation, vaporization, ablation, or cutting of skin in dermatology and plastic/aesthetic surgery (2011)<sup>14</sup>. The Nd:YAG had a similar approval in 2014<sup>15</sup>.

Treatment of vaginal atrophy and other gynecological disorders with LASER devices gained popularity and was marketed for this purpose. In response to this surge, ACOG issued a warning in 2016 clarifying that the FDA had not approved the use of these devices for the

treatment of vulvovaginal atrophy <sup>16</sup>. Despite this announcement, claims that the devices had received FDA approval for such conditions were circulated <sup>17,18</sup>.

Several authors <sup>19,20</sup> and groups, such as the International Society for the Study of Vulvovaginal Disease (ISSVD) <sup>10</sup> and the Society of Obstetricians and Gynaecologists of Canada (SOGC) <sup>21</sup>, have raised concerns about the lack of evidence sustaining the use of LASER technologies for these gynecological indications. Finally, on the 30th July 2018, the FDA issued a warning that the effectiveness and safety of energy-based devices (LASER and radiofrequency) for urinary incontinence, vaginal “rejuvenation” or cosmetic vaginal procedures has not been established <sup>22</sup>.

The executive council of the International Society for the Study of Vulvovaginal Disease (ISSVD) and the board of trustees of the International Continence Society (ICS) acknowledge the need to establish scientifically-based recommendations on the new uses of LASER in their fields. This best practice document has therefore been developed to provide guidance on the use of LASER for the treatment of gynecological and urogynecological conditions and to educate providers about the weaknesses of the available data.

## Material and methods

The ISSVD and the ICS identified and invited members to develop this project; participants were assigned a specific topic to be thoroughly researched and summarized in order to produce recommendations. The project was developed between January and September 2018. The development of this document followed the ICS White Paper Standard Operating Procedures <sup>23</sup>.

Literature searches were performed using Pubmed, Google Scholar, Ovid, Cochrane, and Embase to identify relevant papers. Search results were limited to papers written in English and published prior to June 2018.

Search strings for each topic were:

- Vaginal atrophy/“rejuvenation”:  
“genitourinary syndrome of menopause”, “vulvovaginal atrophy”, “atrophic vaginitis”, “vaginal atrophy”, “vaginal rejuvenation”, “menopause” and “LASER”.
- Urinary incontinence and/or pelvic organ prolapse:  
“urinary incontinence”, “incontinence”, “prolapse”, “POP”, “pelvic organ prolapse”, “cystocele”, “rectocele”, “hysterocele” and “LASER”.
- Vaginal laxity:  
“vaginal tightening”, “vaginal laxity syndrome” and “LASER”.
- Vulvodynia:

“vulvodynia”, “vestibulodynia” and “LASER”.

- Lichen sclerosus:  
“lichen sclerosus” and “LASER”.
- Other possible uses of LASER:  
“bleaching”, “whitening”, “brightening” “labiaplasty”, “labioplasty”,  
“nymphoplasty” and “LASER”.

Evidence was graded according to the Centre of Evidence Based-Medicine’s “Levels of Evidence for Therapeutic Studies” and recommendations according to the American Society of Plastic Surgeons’ “Grade Practice Recommendations”<sup>24</sup>.

After discussion and consensus among all participants, the final version of the text was approved by the Executive Council of the ISSVD and the Board of Trustees of the ICS.

## Basic science evidence

### Proposed mechanism of action of LASER on skin and vaginal tissue

Human skin is comprised of three layers: the epidermis, the dermis, and the subcutaneous fat<sup>25</sup>. Currently, the hypothesized mechanism by which the LASER rejuvenates the vaginal mucosal epithelium has been developed based on the effects of LASER on epidermal skin epithelium. The LASER is believed to induce controlled injury to the epithelial layer of the skin, which stimulates tissue repair and remodelling<sup>26</sup>. Wound repair in skin epithelium is a well-defined process characterized by inflammation, proliferation leading to tissue restoration, and tissue remodelling<sup>27</sup>. LASER is believed to normalize the cycle of collagenesis and collagenolysis<sup>28–30</sup> by inducing break down of disorganized collagen fibrils<sup>31</sup>, creating more organized collagen bundles, and decreasing collagen bundle thickness and density<sup>32</sup>.

Similar to skin, the vaginal wall is composed of three histologically unique layers. The most superficial layer of the vaginal mucosa is made up of stratified squamous epithelium but, unlike the skin epidermis, is devoid of keratinocytes and is therefore non-keratinized. Also unlike skin, vaginal tissue undergoes a number of discrete histologic changes during menopause. Thinning of the vaginal epithelium, reduced vaginal blood flow, diminished lubrication, increased pH and a change in the vaginal microbiome, as well as decreased elasticity of the vaginal wall can occur<sup>33</sup>.

Neocollagenesis and restoration of the trabecular architecture of collagen is the proposed basis for vaginal rejuvenation with CO<sub>2</sub> LASER treatment. Investigators have hypothesized that the molecular and histologic changes demonstrated in the skin in response to LASER treatment can be recreated in the vaginal wall. However, given the differences in anatomy as well as histologic changes in response to hormone balance, such as those seen during menopause, it is unclear whether the effects of the LASER on skin could be expected for the vaginal wall.

In 2011, Gaspar *et al.* demonstrated that vaginal fractional CO<sub>2</sub> LASER treatment increased the thickness of the vaginal epithelium and increased the fibrillary component of the extracellular matrix<sup>34</sup>. In 2015, Salvatore *et al.* described fibrillogenesis and neocollagenesis of vaginal tissue following vaginal LASER treatment in postmenopausal women<sup>35</sup>. Zerbinati *et al.* in 2015 carried out a similar study and examined the tissue of postmenopausal patients with severe symptoms of GSM following CO<sub>2</sub> LASER treatment. They concluded that the histological changes seen support the theory that the LASER stimulates fibroblasts to produce collagen<sup>36</sup>. It is unclear, however, if these histologic changes following LASER treatment can be directly correlated with improvement of clinical symptoms, as no control group was used (discussed in 3.2).

Current published literature on the specific use of LASER in the vagina for the treatment of GSM is limited in the basic science results as well as clinical outcomes and the potential correlation to the histology findings (level of evidence 3b/4, grade of recommendation C). Thus, clinical conclusions drawn from these studies are highly speculative. (Table 1)

### Histological effects

There is little known about the histology of the vaginal mucosa after LASER therapy for vaginal rejuvenation or functional remodelling. What is reported is based on small studies of patients over a short period of time.

Salvatore *et al.* described a single case, with a post-treatment biopsy performed one hour after the CO<sub>2</sub> fractional LASER treatment<sup>37</sup>. The biopsy showed superficial epithelial desquamation. In comparison, animal skin burn studies report signs of injury to include desquamation. Desquamation therefore cannot be interpreted as beneficial remodelling<sup>38</sup>.

In a prospective study from the same group<sup>35</sup>, the authors compared treated vaginal mucosa with mucosa out of the field of therapy from the same patient. They noted neovascularization, neocollagenesis and restoration of the trabecular architecture of collagen in the treated mucosa, which was interpreted as remodelling changes. These biopsies however were taken at the time of the LASER procedure, which would have provided insufficient time for remodelling to occur. In comparison, skin studies have shown changes of wound healing in the first few days after LASER therapy, while restorative changes ensue weeks later<sup>39</sup>. The histology images in the paper mentioned show denuding of the epithelium and different degrees of tissue coagulation, which are consistent with thermal injury.

Zerbinati *et al.* biopsied 5 patients before vaginal treatment, and at one and two months after treatment, which would allow early changes to be appreciated<sup>36</sup>. At one and two months, changes were similar, noting thickened epithelium with superficial shedding, increased dermal papillae with elongated capillaries, giving the epidermal-dermal junction an undulating pattern, increased glycogen in the epithelial cells, and an increase in fibroblast activity. Increased collagen and ground substance have also been described in existing studies<sup>35,36</sup>. The illustrations in Zerbinati's paper show epidermal thickening with acanthosis, and some show parakeratosis and increase in dermal chronic inflammatory cells

<sup>36</sup>. These changes are consistent with repair, as might be seen in lichen simplex chronicus, and alone do not indicate functional remodelling.

Histological changes to the vaginal mucosa following intravaginal LASER therapy have also been compared to a healing vaginal wound at the 2-month time point. A lack of significant capillary density and the increase in cellularity of connective tissue is consistent with this. It has not been confirmed if these changes are favourable for functional remodelling or if they would be sustained at the 6 and 12 month marks <sup>21</sup>.

Interpretation of available studies overall is limited by the lack of long-term follow-up, and hence complications such as scarring may not have been detected <sup>40</sup>. In addition, in a review of the literature on LASER therapy for treating GSM, the authors noted that in one pilot study, the maturation index (a ratio obtained by performing a random cell count of the three major cell types shed from the vaginal squamous epithelium: parabasal, intermediate, and superficial cells) was not considered <sup>3,40</sup>.

In summary, the histology of vaginal LASER “rejuvenation” is not well studied. Only small series have been published, with short follow-up. The changes present after therapy are consistent with reparative changes after a thermal injury. Whether they represent restoration of function has not yet been demonstrated by the histology (level of evidence 4, grade of recommendation C). Further study is needed. (Table 2)

### Impact on the vaginal microbiome

In postmenopausal women, lactobacilli concentration and diversity tend to be lower, while there is a higher diversity of other species <sup>41–43</sup>. These changes have been correlated to the severity of vulvovaginal atrophy symptoms, with normalization using hormonal replacement therapy (HRT) associated with symptom improvement <sup>44</sup>. Based on the limited and controversial evidence demonstrating that vaginal LASExR improves sexual health, vaginal glycogen, and vaginal epithelial thickness, its impact on the vaginal microbiome was evaluated in two studies.

Athanasίου et al. enrolled 53 women with at least one moderate or severe symptom of GSM. The methodology is insufficient as it assumes that one symptom can be used as a surrogate of an entire syndrome <sup>45</sup> and does not describe which scale of severity was used <sup>46</sup>. Following vaginal LASER treatment, the authors report a significant decrease in vaginal pH, but only one third reached a pH lower than 4.5. This decrease was accompanied by an increase in the number of lactobacilli although the techniques used to estimate the lactobacilli population are known to produce an inaccurate estimation. Interestingly, with an inclusion criterion of vaginal pH in the range 4.5-5 at baseline, nearly half of the women had normal vaginal flora according to Nugent and Ison-Hay scores. Following treatment and at the end of the study, this increased to approximately 90%. Colonization by *Candida* was very low (1.9%) and remained stable. The vaginal maturation index improved, but no changes regarding the presence of leukocytes in the vagina were noted.

Becorpi et al. studied the vaginal microbiome in 20 breast cancer survivors treated with 2 sessions of CO<sub>2</sub> LASER. The study reported an almost unchanged microbiome following

treatment. The authors suggested that any possible benefits would be derived from a possible anti-inflammatory effect <sup>47</sup>.

While LASER cannot be recommended as a means to improve the vaginal microbiome, it does not seem to have a deleterious effect on it (level of evidence 2b, grade of recommendation B). (Table 3)

## “Genitourinary syndrome of menopause” & vaginal atrophy

GSM and vulvovaginal atrophy (VVA) are commonly seen in women after menopause. Nearly 50% of postmenopausal women report a vaginal symptom <sup>48</sup>. These symptoms have a significant impact on the quality of life, interfering with the ability to be intimate and enjoy sexual intercourse in 60-70% of sexually active postmenopausal women <sup>49,50</sup>. However, many women consider their symptoms to be a natural part of aging. A survey of American women with a median age of 58 years revealed that 81% did not think VVA was a medical condition, of whom 71% had never sought treatment <sup>5</sup>.

A total of 24 <sup>51-74</sup> clinical studies were identified that investigated transvaginal LASER in women with GSM/VVA. Two studies appeared to include the same study population (separate analyses) <sup>55,67</sup>. The vast majority of the studies used either Er:YAG or fractional, micro ablativ e CO<sub>2</sub> LASER. Some studies used ablativ e Er:YAG LASER <sup>62</sup>. All studies but four were prospective or retrospective case series without a control group. There was one randomized placebo/estriol controlled study <sup>74</sup> (level of evidence 2b) and 3 prospective, non-randomized studies using estradiol gel (or lubricant) as the comparative arm (level of evidence 3b) <sup>51,53,69</sup>.

The clinical outcomes measured were inconsistent throughout the studies. Both subjective non-validated outcome measures and validated clinical outcomes scores were used to assess symptoms, quality of life impact and general health. Samples taken varied from vaginal punch biopsy after treatment in one study <sup>75</sup>, to cytology, and pH evaluation <sup>66</sup> in others. Most studies had a follow up period of less than 12 months, although 3 studies presented 18 to 24 month follow up data. In addition, conflicts of interest were not always clearly specified and adverse events were rarely specifically outlined.

LASER treatment for women with a history of breast cancer and vaginal atrophy was investigated in one paper. In this group of women, hormonal treatment is either contraindicated or patients are reluctant to take low dose topical estrogens for symptoms of GSM. This limited study drew similar conclusions to those reached for other women and was hindered by similar study design flaws <sup>70,71,76</sup>.

Recent developments for the use of LASER in women with GSM/VVA include an international multicentre observational study aiming to evaluate 1500 women treated with vaginal Er:YAG LASER <sup>77</sup>. There is also an ongoing randomized study comparing the effects of CO<sub>2</sub> LASER to vaginal estrogen treatment. This study aims to enrol nearly 200 patients and is expected to finish by the end of 2018 <sup>78</sup>. However there is still a need for a prospective randomized controlled trial with a placebo or sham control arm to understand



the differences. For example a recent meta-analysis demonstrated that 67.7% of the treatment effect for female sexual dysfunction is accounted for by placebo <sup>79</sup>.

The available studies on the use of LASER to treat vaginal atrophy have overall not provided sufficient evidence of efficacy and long term safety (level of evidence 2b/3b, grade of recommendation C). (Table 4)

## **Stress urinary incontinence and/or pelvic organ prolapse**

Some evidence on the role of vaginal LASER exists for its use in urinary incontinence and pelvic organ prolapse <sup>4,34,77,80–86</sup>. The data on its use in stress urinary incontinence comprises mainly short-term observational studies. Participants varied from 19 to 205 women. Treatment response was usually assessed with validated questionnaires and showed favourable outcomes in terms of improvement of symptoms, but only 1 study followed patients for 24 months. None of the studies had a control or placebo group <sup>4,34,80–83</sup>.

There is minimal published data on the use of LASER in treating female pelvic organ prolapse. Its use has been described in women with grade II (prolapse to the hymen) to IV (maximum descent) cystoceles and follow up at 12 months has demonstrated an improvement in prolapse grade, with some patients sustaining the effect at 36 months <sup>86</sup>.

While the use of LASER to treat stress urinary incontinence and/or pelvic organ prolapse may seem appealing, the lack of good quality evidence in the form of multi-centre randomised placebo-controlled trials is concerning.

Use of LASER may lead to serious adverse events such as vaginal burns, scarring, dyspareunia and chronic pain. Although reports of adverse events in the literature is minimal, the sample sizes are small hence minimal reassurance can be taken from this <sup>87</sup>. The histological effects of LASER to the vaginal wall remain unclear leaving further questions regarding the effect of LASER therapy on surgical dissection and outcomes in women who may eventually require reconstructive pelvic or anti-incontinence surgery.

A recent review article looking at the evidence relating to the risks and benefits of intravaginal LASER technology in the management of stress urinary incontinence confirmed that despite the short-term observational studies of small patient numbers demonstrating improvements, there is still insufficient evidence to offer it as an effective modality for the treatment of stress urinary incontinence over alternative managements, such as pelvic floor physiotherapy, incontinence pessaries or continence surgery <sup>21</sup>. Similarly there is insufficient evidence to offer intravaginal LASER therapy for vaginal prolapse (level of evidence 4, recommendation grade D). (Table 5)

## **“Vaginal Laxity Syndrome”**

Vaginal laxity, as a subjective patient complaint, has been described by IUGA and ICS as a feeling of vaginal looseness<sup>9</sup>. Its anatomical definition, quality of life impact and treatment are poorly understood<sup>88</sup> and not widely recognised. “Vaginal laxity syndrome” (VLS) or

even “vaginal hyperlaxity syndrome” are concepts and marketing terminology, with a lack of a standardized definition.

Some believe that VLS is an evolution of the aesthetic designation of “vaginal rejuvenation”<sup>88</sup>. It is described as a disorder derived from the excessive laxity of the vaginal walls, leading to a sensation of looseness, diminished sensation of penile friction, and may be associated with urinary incontinence (urgency or stress)<sup>61</sup>. VLS is considered a consequence of ageing and related to having had vaginal deliveries. The term VLS, and therefore its therapy, vaginal rejuvenation, is not endorsed or formally defined by the leading gynecological societies<sup>11</sup>. However, management of the symptoms have evolved from techniques involving sutures and the adaptation of traditional urogynecological procedures to the use of LASER<sup>61,89</sup> and radiofrequency procedures<sup>90–98</sup>.

In 2011, there was an attempt to restore the *rugae* of the vagina in postmenopausal women (“vaginal rugation rejuvenation”), by vaporization of the vaginal walls in order to create parallel grooves. The procedure was performed in women with a sensation of a loose or smooth vagina. In a small observational trial (10 patients in each arm), there was an apparent improvement of sexual function and no complications. The design and small sample size did not allow the authors to draw conclusions from the study<sup>89</sup>.

In 2014, Lee evaluated two different protocols (15 patients in each arm), using Er:YAG LASER. Women in both groups were evaluated 2 months after the procedure. There were no complications or adverse effects, although mild heating of the vagina and ecchymosis were reported. There was an objective (perineometer) and subjective improvement for 70% of the subjects, with 76.6% of their partners reporting an improvement in sexual function. No validated scales were used for evaluation of the sexual function. A histological improvement was also suggested, but no analysis was shown<sup>61</sup>.

In total, 2 small studies on the use of LASER in vaginal relaxation syndrome comprising 51 women showed non-validated patient-reported improvements in sexual experience after LASER treatment but follow up was short term<sup>84,85</sup>. We could not find any study in the literature evaluating the role of CO<sub>2</sub> LASER for vaginal tightening specifically. Several studies have arisen using radiofrequency. The available data, in comparison to that for LASER use, are more robust and sustained by studies with a better design. So far, there has been no comparison between the different types of energy.

There are no data supporting the recommendation of performing “vaginal rugation rejuvenation” or showing its safety (level of evidence 4, grade of recommendation D). (Table 6)

## Vulvodynia

Vulvodynia is a chronic, complex pain disorder of multifactorial aetiology that can be difficult to manage. It is common, affecting more than 4-16% of women and can occur at any age, including postmenopausal women, particularly among those who remain sexually active<sup>99,100</sup>.

In 2015, the ISSVD, the International Society for the Study of Sexual Health of Women (ISSWSH) and the International Pelvic Pain Society (IPPS) adopted new terminology for vulvar pain and vulvodynia<sup>101</sup>. It is classified according to the site of pain (generalized or localized), the need of a stimulus (provoked, not provoked [spontaneous], or mixed), and the onset (primary or secondary). Treatment is difficult, and rapid resolution is unusual even with proper treatment. Decrease in pain may take weeks to months and may not be complete. No single treatment is successful in all women<sup>102</sup>. The vulvodynia treatment algorithm includes vulvar skin care guidelines, topical, oral and injectable medications, pudendal nerve block, biofeedback, physical therapy, dietary modifications, cognitive behavioural therapy, sexual counselling and surgery, as well as alternative therapies such as acupuncture and hypnotherapy<sup>103</sup>.

Few studies have been conducted evaluating the usefulness of LASER therapy in the treatment of vulvodynia<sup>59,104,105</sup>.

A retrospective study indicated less pain with sexual intercourse among 24 of 37 women treated with LASER pulse therapy for vestibulodynia. However, 35% of the patients in the study required a vestibulectomy to control the symptoms<sup>104</sup>.

In 2016, in a study involving 70 patients who underwent fractional micro-ablative CO<sub>2</sub> LASER treatment for vestibular pain plus vestibulodynia (n = 37) or menopausal patients (age > 50 years) who presented with vulvar pain secondary to GSM/VVA (n = 33), showed statistically significant improvement of dyspareunia and pain scores, with gradual improvement over each time point persisting through 4-month follow-up. Average overall vestibular health index score (a non-validated score, that intends to assess vestibular atrophy) improved significantly in the two groups after each of the three individual treatments. There was no statistically significant difference in outcomes between the two study groups<sup>59</sup>.

More recently, a placebo-controlled, double-blinded, randomized clinical trial involving 34 women aged 19-46 years old using low-level LASER therapy (LLLT) versus placebo showed Clinical Pain Report improvement in 78% in the LLLT group and 44% in the placebo group. Nevertheless, other measurable parameters (Q-tip test, intercourse pain on the Visual Analog Scale, and tampon tests before and after treatment, severity of discomfort in daily activities and/or in daily pain intensity) did not show a difference between groups. Although none of the patients reported side effects during the study, recurrence of pain was evidenced in 33 % of the LLLT group<sup>105</sup>.

Interestingly, LASER (pulse or scan), used to treat vulvar mucosa disease (warts or vulvar HSIL) has been shown to be a possible cause of chronic vulvar pain<sup>106</sup>.

The few available studies concerning the treatment of vulvodynia with LASER have not proven it to be efficacious or safe, therefore its use should not be considered in these patients (level of evidence 2b, grade of recommendation B).

## Lichen sclerosus

Lichen sclerosus (LS) is a complex chronic inflammatory autoimmune dermatosis that can be found in patients of any age and race<sup>107</sup>. It is 10 times more common in females<sup>108</sup>. The incidence rate is around 10 per 100.000 woman-years, rising to over 30 per 100.000 woman-years in women older than 55<sup>109</sup>. The main symptoms are itching, burning and dyspareunia, with impact on health-related quality of life<sup>110</sup>.

Vulvar LS (VLS) clinical aspects can vary significantly. Differentiated vulvar intraepithelial neoplasia (dVIN), the HPV-independent pathway to vulvar carcinoma, must be suspected and biopsied promptly in treatment-resistant cases, and in the presence of erosion or hyperkeratotic plaques in a field of VLS<sup>111</sup>. The risk of vulvar cancer in VLS is estimated to be 2-5%, with higher risk in older women and with longer duration of disease<sup>109,112,113</sup>. Long term therapy, however, seems to be protective<sup>114,115</sup>. Current guidelines recommend the use of super-potent topical corticosteroids as first-line. Both the risk of cancer and the need of long term follow up must be taken into account when new treatment options are presented for LS, given the proven efficacy of topical corticosteroids<sup>116-119</sup>

In 1991 a Canadian study reported 7 women with VLS refractory to topical testosterone who became asymptomatic following LASER ablation (600-900W/cm<sup>2</sup> depth of tissue destruction 2 mm under general anaesthesia). No biopsy after treatment was performed to confirm histological changes<sup>120</sup>. Similar results and depth of tissue vaporization was described by Kartamaa in 2 patients with VLS<sup>121</sup>. The aim to “remove the epithelium and papillary dermis involved in LS” for resolution of symptoms was reported in another 2 cases study in the absence of post treatment biopsies<sup>122</sup>.

In a recent case series<sup>123</sup>, 5 women underwent fractional CO<sub>2</sub> LASER treatment for hyperkeratotic VLS not responding to topical clobetasol. After 1-3 treatments with CO<sub>2</sub> LASER, energy 140-170 MJ and treatment depth 150 µm, symptoms had complete resolution in 3, partial in one, and one was asymptomatic before treatment. Median follow up was 9 months (range 6-48). Re-epithelialization occurred in 3-4 weeks in all cases. Hyperkeratosis recurred after 6-8 months. In all patients, maintenance treatment was clobetasol. The objective to ablate the improper function of dermal epidermal zone, creating a new zone with proper function, is not supported by the published data.

All the papers considered are studies with very small series of patients, who did not undergo randomization, with short follow-up time. Neither visual analogue scale (VAS) for symptoms, nor details of pre/post treatment vulvar lesions were reported. The lack of description of the corticosteroid regimen utilized is another common weakness in the reported studies that prevent correct analysis of CO<sub>2</sub> LASER-treated patients and interpretation of its true efficacy. Furthermore, injuries (mechanical, chemical, burning, etc.) can be a cause of isomorphic or Koebner (Köbner) phenomenon in LS patients<sup>124</sup>. Currently, there is no evidence that fractional LASER is exempt from this risk in LS patients. Up to now the description of CO<sub>2</sub> LASER as a safe and effective therapy for recalcitrant VLS has no evidence within the literature data (level of evidence 4, grade of recommendation C) (Table 8)

## Other possible uses of LASER (vulvar bleaching/whitening /brightening, labiaplasty)

While the labia tend to be more pigmented than the surrounding structures, some women have the desire to whiten it. It can represent up to 6.8% of the patients consulting a gynecological aesthetic unit <sup>125</sup>. This procedure, using LASER, is commonly offered, but there are no studies showing its efficacy or safety. We could only find reference to it in one study, but LASER was done in combination with other procedures, such as labiaplasty, augmentation of the labia *majora*, *mons pubis* liposuction, or vaginal tightening <sup>126</sup>. Of note, even the use of LASER for hair removal has been related to serious urogynecological complications, such as labial adhesion with cryptomenorrhea, and acute urinary retention <sup>127</sup>. In one survey, 85.9% of physicians stated that there is no medical indication for the performance of such procedures <sup>128</sup>.

Labiaplasty is one of the most performed female cosmetic genital procedures worldwide. There are several techniques described, some with the use of LASER. Despite the misleading anatomical description, the procedure coined “Designer LASER Vaginoplasty” is also a form of labiaplasty <sup>129</sup>. Of note, this procedure has been considered unethical by the American College of Obstetricians and Gynaecologists, due to the lack of supporting evidence <sup>11</sup>.

In 2006, the use of Nd:YAG LASER for the treatment of hypertrophy of the labia *minora* was reported. In a series of 55 women (including 4 children 10-15 years old), of whom 11 (20%) lacked the authors’ established criteria of hypertrophy of the labia *minora* (>2 cm of width), there were no intraoperative complications, dehiscence occurred in 5.4%, and there was no pain after 7 days. Satisfaction rates were very high (>90%) <sup>130</sup>. In another series, comprising 231 women who underwent reduction of the labia *minora* using CO<sub>2</sub> LASER to make a lambda shaped incision, a 100% satisfaction rate was reported, along with a low complication rate (11 wound dehiscence, 3 hematomas, 1 acute bleed requiring return to the operating room); however, there is no reference to the duration of follow up <sup>131</sup>. More recently, in a study involving 112 women aged 15-62 years old using CO<sub>2</sub> LASER, improvement in overall satisfaction and comfort during intercourse were reported. The rate of complications and the duration of follow-up were not mentioned <sup>132</sup>.

None of the studies have included a control group. In at least two of the studies children were enrolled. In at least one study, women did not meet the (controversial) study definition of hypertrophy of the labia *minora*. There is no universally accepted definition of hypertrophy of the labia *minora*; some authors have described it as a width superior to 4 or 5 cm, or protruding beyond the labia *majora*<sup>133</sup>. There is no correlation between the size of the labia *minora* and the ability to feel sexual pleasure or orgasm<sup>134</sup>. Brodie et al evaluated normal adolescents and pointed that there can be significant variance in the size of labia *minora*, according to being stretched or non-stretched (1-13 mm), that asymmetry is common (>50% of adolescent women), and that the mean width of labia *minora* was 10 mm (3-70 mm) (unstretched) and 20.5 mm (5-62 mm) (stretched)<sup>135</sup>. If those definitions were applied to adolescents, a significant number would be considered “abnormal”!

There appears to be no sufficient good quality data showing the safety of or justification of the use of LASER for gynaecological cosmetic indications in general (level of evidence 4, grade of recommendation C). It appears, however, to be safe for labiaplasty (level of evidence 3b grade of recommendation C). (table 9)

## Conclusions

Advances in science, including medicine, are often questioned. However, as science evolves, we must remain committed to maintaining a high ethical standard. The 4 pillars of ethics—autonomy, beneficence, non-maleficence, and justice<sup>136</sup>—must guide medicine in both clinical practice and research.

The lack of quality studies regarding the use of trans-vaginal and vulvar LASER for gynaecology and urology raises the question of whether such therapy provides beneficence and absence of maleficence; its use also hinders the patient's autonomy and choice. In order to give truly informed consent, there is need for clear and definitive information. Many questions remain unanswered from the safety profile of the therapies, comparison to current treatments, and long-term effects on tissues. Interestingly, the majority of LASER research carried out so far has been industry-funded, leading to significant risk of bias. There is an attraction to this office procedure which is profitable to the individual provider, however this should not drive un-guided practice.

Controversial applications regarding the use of LASER that have been promoted recently without rigid scientific validation, regulation, or oversight include the reconstructive therapy for “vaginal rejuvenation”, and design LASER vaginoplasty<sup>137</sup>. The deceptive marketing of unproven treatments may not only cause injuries but may also keep patients from accessing appropriate and recognized therapies. It is imperative that providers protect patients from potential unknown harm due to the understudied clinical application of LASER technology and protect themselves from potentially indefensible lawsuits.

While there is potential for utilization of LASER to treat some proposed clinical conditions, most commonly vaginal atrophy and stress urinary incontinence, the scientific evidence remains exploratory. The existing literature is almost all post-marketing, in the setting of daily practice, rather than within controlled clinical trials. As with other innovations this is unacceptable, as safety must be proven before reaching the consumer. LASER has been available for use and disseminated among clinicians before sufficient data regarding quality, safety and efficacy were provided. Use of this technology prior to rigorous scientific examination may end in adversity, as has been demonstrated by previous technologies such as vaginal mesh for prolapse repair and power tissue morcellation<sup>138</sup>.

Although LASER technology seems promising for selected indications, long-term efficacy and safety data are lacking. In order to elucidate its optimal clinical application, LASER therapy must be evaluated in rigorous, well-designed studies that are of appropriate time scale, randomized and sham-controlled, to evaluate safety and efficacy. Therefore, despite its appeal to clinicians and women, assumptions cannot yet be made regarding the durability of this treatment nor its long-term effects, either positive or negative to date. Until further

literature emerges, this technology should be considered experimental and remain within the domain of clinical trials or with special arrangements for clinical governance, consent and audit.

## ACKNOWLEDGMENTS

The authors thank Debbie Roepe and Dan Snowdon for facilitating the development and publication of this best practice consensus document.

## REFERENCES

1. Schellhas HF. Laser surgery in gynecology. *Surg Clin North Am.* 1978;58(1):151–166. <http://www.ncbi.nlm.nih.gov/pubmed/148108>. [PubMed: 148108]
2. Herrmann TRW, Bach T. Update on lasers in urology 2015. *World J Urol.* 2015;33(4):457–460. doi: 10.1007/s00345-015-1534-3. [PubMed: 25777277]
3. Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. *Climateric.* 2014;17(4):363–369. doi: 10.3109/13697137.2014.899347.
4. Ogrinc UB, Sen ar S, Lenasi H. Novel minimally invasive laser treatment of urinary incontinence in women. *Lasers Surg Med.* 2015;47(9):689–697. doi:10.1002/lsm.22416. [PubMed: 26388213]
5. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women’s EMPOWER Survey: Identifying Women’s Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. *J Sex Med.* 2017;14(3):413–424. doi:10.1016/j.jsxm.2017.01.010. [PubMed: 28202320]
6. Portman DJ, Gass MLS, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society.1. Portman, D. J., Gass, M. L. S. & Vulvovaginal Atrophy Terminolo. *Maturitas.* 2014;79(3):349–354. doi:10.1016/j.maturitas.2014.07.013. [PubMed: 25179577]
7. Vieira-Baptista P, Marchitelli C, Haefner HK. The “Genitourinary Syndrome of Menopause”: A Leap Forward? *J Low Genit Tract Dis.* 2015;19(4):362–363. doi:10.1097/LGT.000000000000127. [PubMed: 26083333]
8. Pauls RN, Fellner AN, Davila GW. Vaginal laxity: a poorly understood quality of life problem; a survey of physician members of the International Urogynecological Association (IUGA). *Int Urogynecol J.* 2012;23(10):1435–1448. doi:10.1007/s00192-012-1757-4. [PubMed: 22669419]
9. Rogers RG, Pauls RN, Thakar R, et al. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for the assessment of sexual health of women with pelvic floor dysfunction. *Neurourol Urodyn.* 2018;37(4):1220–1240. doi: 10.1002/nau.23508. [PubMed: 29441607]
10. Vieira-Baptista P, Almeida G, Bogliatto F, et al. International Society for the Study of Vulvovaginal Disease Recommendations Regarding Female Cosmetic Genital Surgery. *J Low Genit Tract Dis.* 2018;1. doi:10.1097/LGT.0000000000000412.
11. ACOG Committee Opinion No. 378: Vaginal “rejuvenation” and cosmetic vaginal procedures. *Obstet Gynecol.* 2007;110(3):737–738. doi:10.1097/01.AOG.0000263927.82639.9b. [PubMed: 17766626]
12. 510(K) Summary. doi:[https://www.accessdata.fda.gov/cdrh\\_docs/pdf10/K101904.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf10/K101904.pdf).
13. 510(K) Summary DEKA SmartXide2 Laser System. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf13/k133895.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf13/k133895.pdf).
14. 510(K) Summary Apex Er:YAG / IPL System. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf11/K110304.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf11/K110304.pdf).
15. 510(k) Summary for RevLite 0-Switched Nd: YAG Laser System. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf13/k133254.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf13/k133254.pdf).
16. Fractional Laser Treatment of Vulvovaginal Atrophy and U.S. Food and Drug Administration Clearance. <https://www.acog.org/Clinical-Guidance-and-Publications/Position-Statements/>

[Fractional-Laser-Treatment-of-Vulvovaginal-Atrophy-and-US-Food-and-Drug-Administration-Clearance.](#)

17. Streicher LF. Vulvar and vaginal fractional CO2 laser treatments for genitourinary syndrome of menopause. *Menopause*. 2018;25(5):571–573. doi:10.1097/GME.0000000000001049. [PubMed: 29406425]
18. Vieira-Baptista P, Damaser M, Digesu A, Marchitelli C, Preti M, Stockdale C. To the Editor. *Menopause*. 7 2018;1. doi:10.1097/GME.0000000000001165.
19. Digesu GA, Swift S. Laser treatment in urogynaecology and the myth of the scientific evidence. *Int Urogynecol J*. 2017;28(10):1443–1444. doi:10.1007/s00192-017-3458-5. [PubMed: 28842718]
20. Singh A, Swift S, Khullar V, Digesu GA. Laser vaginal rejuvenation: not ready for prime time. *Int Urogynecol J*. 2015;26(2):163–164. doi:10.1007/s00192-014-2588-2. [PubMed: 25477142]
21. Walter J-E, Larochelle A. No. 358-Intravaginal Laser for Genitourinary Syndrome of Menopause and Stress Urinary Incontinence. *J Obstet Gynaecol Canada*. 2018;40(4):503–511. doi:10.1016/j.jogc.2017.11.040.
22. FDA Warns Against Use of Energy-Based Devices to Perform Vaginal “Rejuvenation” or Vaginal Cosmetic Procedures: FDA Safety Communication. <https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm615013.htm>.
23. Standard Operating Procedure: ICS White Paper. <https://www.ics.org/committees/education/icssops>.
24. Burns PB, Rohrich RJ, Chung KC. The Levels of Evidence and Their Role in Evidence-Based Medicine. *Plast Reconstr Surg*. 2011;128(1):305–310. doi:10.1097/PRS.0b013e318219c171. [PubMed: 21701348]
25. Bologna JL, Schaffer JV., Cerroni L. *Dermatology*.; 2018.
26. Ross E V, McKinlay JR, Anderson RR. Why does carbon dioxide resurfacing work? A review. *Arch Dermatol*. 1999;135(4):444–454. [PubMed: 10206052]
27. Eming SA, Wynn TA, Martin P. Inflammation and metabolism in tissue repair and regeneration. *Science*. 2017;356(6342):1026–1030. doi:10.1126/science.aam7928. [PubMed: 28596335]
28. Lee S jun, Suh DH, Lee JM, Song KY, Ryu HJ. Dermal Remodeling of Burn Scar by Fractional CO2Laser. *Aesthetic Plast Surg*. 2016;40(5):761–768. doi:10.1007/s00266-016-0686-x. [PubMed: 27519176]
29. Tierney EP, Hanke CW, Petersen J. Ablative fractionated CO 2 laser treatment of photoaging: A clinical and histologic study. *Dermatologic Surg*. 2012;38(11):1777–1789. doi:10.1111/j.1524-4725.2012.02572.x.
30. Alster TS, Tanzi EL, Lazarus M. The use of fractional laser photothermolysis for the treatment of atrophic scars. *Dermatol Surg*. 2007;33(3):295–299. doi:10.1111/j.1524-4725.2007.33059.x. [PubMed: 17338686]
31. Levi B, Ibrahim A, Mathews K, et al. The Use of CO2 Fractional Photothermolysis for the Treatment of Burn Scars. *J Burn Care Res*. 2016;37(2):106–114. doi:10.1097/BCR.0000000000000285. [PubMed: 26536539]
32. El-Zawahry BM, Sobhi RM, Bassiouny DA, Tabak SA. Ablative CO2 fractional resurfacing in treatment of thermal burn scars: an open-label controlled clinical and histopathological study. *J Cosmet Dermatol*. 2015;14(4):324–331. doi:10.1111/jocd.12163. [PubMed: 26260018]
33. Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. *Maturitas*. 2014;79(3):349–354. doi:10.1016/j.maturitas.2014.07.013. [PubMed: 25179577]
34. Gaspar A, Addamo G, Brandi H. Vaginal Fractional CO 2 Laser: A Minimally Invasive Option for Vaginal Rejuvenation. *Am J Cosmet Surg*. 2011;28(3):156–162. doi:10.1177/074880681102800309.
35. Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. *Menopause*. 2015;22(8):845–849. doi:10.1097/GME.0000000000000401. [PubMed: 25608269]



36. Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. *Lasers Med Sci.* 2015;30(1):429–436. doi:10.1007/s10103-014-1677-2. [PubMed: 25410301]
37. Salvatore S, França K, Lotti T, et al. Early Regenerative Modifications of Human Postmenopausal Atrophic Vaginal Mucosa Following Fractional CO<sub>2</sub> Laser Treatment. *Open Access Maced J Med Sci.* 2018;6(1):6. doi:10.3889/oamjms.2018.058. [PubMed: 29483970]
38. Chhibber T, Wadhwa S, Chadha P, Sharma G, Katare OP. Phospholipid structured microemulsion as effective carrier system with potential in methicillin sensitive *Staphylococcus aureus* (MSSA) involved burn wound infection. *J Drug Target.* 2015;23(10):943–952. doi:10.3109/1061186X.2015.1048518. [PubMed: 26004269]
39. Tadir Y, Gaspar A, Lev-Sagie A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: Consensus and controversies. *Lasers Surg Med.* 2017;49(2):137–159. doi:10.1002/lsm.22637. [PubMed: 28220946]
40. Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. *Int Urogynecol J.* 2017;28(5):681–685. doi:10.1007/s00192-017-3282-y. [PubMed: 28154914]
41. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. doi:10.1073/pnas.1002611107.
42. Hummelen R, Macklaim JM, Bisanz JE, et al. Vaginal Microbiome and Epithelial Gene Array in Post-Menopausal Women with Moderate to Severe Dryness Highlander SK, ed. *PLoS One.* 2011;6(11):e26602. doi:10.1371/journal.pone.0026602. [PubMed: 22073175]
43. Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. *Menopause.* 2014;21(5):450–458. doi:10.1097/GME.0b013e3182a4690b. [PubMed: 24080849]
44. Heinemann C, Reid G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. *Can J Microbiol.* 2005;51(9):777–781. doi:10.1139/w05-070. [PubMed: 16391657]
45. Vieira-Baptista P, Marchitelli C, Haefner HK, Donders G, Pérez-López F. Deconstructing the genitourinary syndrome of menopause. *Int Urogynecol J.* 2017;28(5):675–679. doi:10.1007/s00192-017-3295-6. [PubMed: 28293790]
46. Athanasiou S, Pitsouni E, Antonopoulou S, et al. The effect of microablative fractional CO<sub>2</sub> laser on vaginal flora of postmenopausal women. *Climacteric.* 2016;19(5):512–518. doi:10.1080/13697137.2016.1212006. [PubMed: 27558459]
47. Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO<sub>2</sub> laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. *Lasers Med Sci.* 3 2018. doi:10.1007/s10103-018-2471-3.
48. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. *Climacteric.* 2012;15(1):36–44. doi:10.3109/13697137.2011.647840. [PubMed: 22168244]
49. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. *Climacteric.* 2016;19(2):188–197. doi:10.3109/13697137.2015.1107039. [PubMed: 26581580]
50. Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey. *Menopause.* 2014;21(2):137–142. doi:10.1097/GME.0b013e318295236f. [PubMed: 23736862]
51. Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. *Climacteric.* 2015;18(5):757–763. doi:10.3109/13697137.2015.1045485. [PubMed: 26029987]
52. Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause. *Menopause.* 2017;24(3):316–319. doi:10.1097/GME.0000000000000761. [PubMed: 28231079]
53. Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. *Lasers Surg Med.* 2017;49(2):160–168. doi:10.1002/lsm.22569. [PubMed: 27546524]

54. Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO<sub>2</sub> laser for vulvovaginal atrophy: a pilot study. *Climacteric*. 2014;17(4):363–369. doi: 10.3109/13697137.2014.899347. [PubMed: 24605832]
55. Sokol ER, Karram MM. Use of a novel fractional CO<sub>2</sub> laser for the treatment of genitourinary syndrome of menopause. *Menopause*. 2017;24(7):810–814. doi:10.1097/GME.0000000000000839. [PubMed: 28169913]
56. Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO<sub>2</sub> laser. *Maturitas*. 2015;80(3):296–301. doi:10.1016/j.maturitas.2014.12.006. [PubMed: 25596815]
57. Athanasiou S, Pitsouni E, Antonopoulou S, et al. The effect of microablative fractional CO<sub>2</sub> laser on vaginal flora of postmenopausal women. *Climacteric*. 2016;19(5):512–518. doi: 10.1080/13697137.2016.1212006. [PubMed: 27558459]
58. Behnia-Willison F, Sarraf S, Miller J, et al. Safety and long-term efficacy of fractional CO<sub>2</sub> laser treatment in women suffering from genitourinary syndrome of menopause. *Eur J Obstet Gynecol Reprod Biol*. 2017;213:39–44. doi:10.1016/j.ejogrb.2017.03.036. [PubMed: 28419911]
59. Murina F, Karram M, Salvatore S, Felice R. Fractional CO<sub>2</sub> Laser Treatment of the Vestibule for Patients with Vestibulodynia and Genitourinary Syndrome of Menopause: A Pilot Study. *J Sex Med*. 2016;13(12):1915–1917. doi:10.1016/j.jsxm.2016.10.006. [PubMed: 27864031]
60. Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO<sub>2</sub> laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer. *Menopause*. 2016;23(10):1108–1113. doi:10.1097/GME.0000000000000672. [PubMed: 27648595]
61. Lee MS. Treatment of Vaginal Relaxation Syndrome with an Erbium:YAG Laser Using 90o and 360o Scanning Scopes: A Pilot Study & Short-term Results. *LASER Ther*. 2014;23(2):129–138. doi:10.5978/islm.14-OR-11. [PubMed: 25071312]
62. Mothes AR, Runnebaum M, Runnebaum IB. Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. *J Cancer Res Clin Oncol*. 2018;144(5):955–960. doi:10.1007/s00432-018-2614-8. [PubMed: 29487993]
63. Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO<sub>2</sub> laser in women with vulvovaginal atrophy. *Climacteric*. 2015;18(2):219–225. doi: 10.3109/13697137.2014.975197. [PubMed: 25333211]
64. Siliquini GP, Tuninetti V, Bounous VE, Bert F, Biglia N. Fractional CO<sub>2</sub> laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women. *Climacteric*. 2017;20(4):379–384. doi:10.1080/13697137.2017.1319815. [PubMed: 28503946]
65. Filippini M, Del Duca E, Negosanti F, et al. Fractional CO<sub>2</sub> Laser: From Skin Rejuvenation to Vulvo-Vaginal Reshaping. *Photomed Laser Surg*. 2017;35(3):171–175. doi:10.1089/pho.2016.4173. [PubMed: 28056209]
66. Pitsouni E, Grigoriadis T, Tsiveleka A, Zacharakis D, Salvatore S, Athanasiou S. Microablative fractional CO<sub>2</sub> -laser therapy and the genitourinary syndrome of menopause: An observational study. *Maturitas*. 2016;94:131–136. doi:10.1016/j.maturitas.2016.09.012. [PubMed: 27823733]
67. Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO<sub>2</sub> laser system for the treatment of vulvovaginal atrophy. *Menopause*. 2016;23(10):1102–1107. doi:10.1097/GME.0000000000000700. [PubMed: 27404032]
68. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO<sub>2</sub> laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. *Arch Gynecol Obstet*. 2016;294(4):841–846. doi: 10.1007/s00404-016-4118-6. [PubMed: 27170261]
69. Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. *Climacteric*. 2018;21(2):148–152. doi:10.1080/13697137.2018.1436538. [PubMed: 29436235]
70. Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO<sub>2</sub> laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments. *Menopause*. 2018;25(6):657–662. doi:10.1097/GME.0000000000001053. [PubMed: 29286986]

71. Pagano I, Gieri S, Nocera F, et al. Evaluation of the CO2 Laser Therapy on Vulvo-Vaginal Atrophy (VVA) in Oncological Patients: Preliminary Results. *J Cancer Ther.* 2017;8(5):452–463. doi: 10.4236/jct.2017.85039. [PubMed: 29104812]
72. Arroyo C Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women. *Int J Womens Health.* 2017;Volume 9:591–595. doi: 10.2147/IJWH.S136857. [PubMed: 28894392]
73. Pieralli A, Bianchi C, Longinotti M, et al. Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms. *Arch Gynecol Obstet.* 2017;296(5):973–978. doi:10.1007/s00404-017-4504-8. [PubMed: 28866727]
74. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. *Menopause.* 7 2017:1. doi:10.1097/GME.0000000000000955.
75. Lapii GA, Yakovleva AY, Neimark AI. Structural Reorganization of the Vaginal Mucosa in Stress Urinary Incontinence under Conditions of Er:YAG Laser Treatment. *Bull Exp Biol Med.* 2017;162(4):510–514. doi:10.1007/s10517-017-3650-0. [PubMed: 28243906]
76. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. *Arch Gynecol Obstet.* 2016;294(4):841–846. doi: 10.1007/s00404-016-4118-6. [PubMed: 27170261]
77. Gambacciani M, Torelli MG, Martella L, et al. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. *Climacteric.* 2015;18 Suppl 1(sup1):43–48. doi:10.3109/13697137.2015.1071608. [PubMed: 26366800]
78. Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy (VeLVET). <https://clinicaltrials.gov/ct2/show/study/NCT02691936>.
79. Weinberger JM, Houman J, Caron AT, et al. Female Sexual Dysfunction and the Placebo Effect. *Obstet Gynecol.* 2018;132(2):453–458. doi:10.1097/AOG.0000000000002733. [PubMed: 29995725]
80. Fiston N, Fiston I, Guštek ŠF, et al. Minimally invasive, non-ablative Er:YAG laser treatment of stress urinary incontinence in women—a pilot study. *Lasers Med Sci.* 2016;31(4):635–643. doi: 10.1007/s10103-016-1884-0. [PubMed: 26861984]
81. Fiston N, Fiston I, Lukanovi A, Guštek ŠF, Turina ISB, Frani D. First assessment of short-term efficacy of Er:YAG laser treatment on stress urinary incontinence in women: prospective cohort study. *Climacteric.* 2015;18(sup1):37–42. doi:10.3109/13697137.2015.1071126. [PubMed: 26366799]
82. Pardo JI, Solà VR, Morales AA. Treatment of female stress urinary incontinence with Erbium-YAG laser in non-ablative mode. *Eur J Obstet Gynecol Reprod Biol.* 2016;204:1–4. doi:10.1016/j.ejogrb.2016.06.031. [PubMed: 27448169]
83. Gaspar A, Brandi H. Non-ablative erbium YAG laser for the treatment of type III stress urinary incontinence (intrinsic sphincter deficiency). *Lasers Med Sci.* 2017;32(3):685–691. doi:10.1007/s10103-017-2170-5. [PubMed: 28210823]
84. Gavia J, Lanz J. Laser Vaginal Tightening (LVT) – evaluation of a novel noninvasive laser treatment for vaginal relaxation syndrome. *J Laser Heal Acad.* 2012;1:59–66.
85. Bizjak-Ogrinc U, Sencar S. Non-surgical minimally invasive ER:YAG LASER treatment fo higher-grade cystocele. In: 38th Annual IUGA Meeting, . ; 2013.
86. Bizjak-Ogrinc U, Sencar S, Vizintin Z. #178 3 years follow-up of pelvic organ prolapses treated with Er:YAG laser. *Lasers Surg Med.* 2017;49(S28):63. doi:10.1002/lsm.22650. [PubMed: 27327898]
87. Food and Drug Administration (FDA). Statement from FDA Commissioner Scott Gottlieb MD, on efforts to safeguard women’s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for “vaginal rejuvenation.” <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm615130.htm>.
88. Palacios S Vaginal hyperlaxity syndrome: a new concept and challenge. *Gynecol Endocrinol.* 2018;34(5):360–362. doi:10.1080/09513590.2017.1418312. [PubMed: 29275641]

89. Ostrzenski A Vaginal Rugation Rejuvenation (Restoration): A New Surgical Technique for an Acquired Sensation of Wide/Smooth Vagina. *Gynecol Obstet Invest.* 2012;73(1):48–52. doi: 10.1159/000329338. [PubMed: 21829003]
90. Lalji S, Lozanova P. Evaluation of the safety and efficacy of a monopolar nonablative radiofrequency device for the improvement of vulvo-vaginal laxity and urinary incontinence. *J Cosmet Dermatol.* 2017;16(2):230–234. doi:10.1111/jocd.12348. [PubMed: 28556393]
91. Vanaman Wilson MJ, Bolton J, Jones IT, Wu DC, Calame A, Goldman MP. Histologic and Clinical Changes in Vulvovaginal Tissue After Treatment With a Transcutaneous Temperature-Controlled Radiofrequency Device. *Dermatol Surg.* 2018;44(5):705–713. doi:10.1097/DSS.0000000000001453. [PubMed: 29701623]
92. Krychman M, Rowan CG, Allan BB, Durbin S, Yacoubian A, Wilkerson D. Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial. *J Women's Heal.* 2018;27(3):297–304. doi:10.1089/jwh.2017.6335.
93. Krychman M, Rowan CG, Allan BB, et al. Effect of Single-Treatment, Surface-Cooled Radiofrequency Therapy on Vaginal Laxity and Female Sexual Function: The VIVEVE I Randomized Controlled Trial. *J Sex Med.* 2017;14(2):215–225. doi:10.1016/j.jsxm.2016.11.322. [PubMed: 28161079]
94. Vicariotto F, DE Seta F, Faoro V, Raichi M. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety. *Minerva Ginecol.* 2017;69(4):342–349. <http://www.ncbi.nlm.nih.gov/pubmed/28608667>. [PubMed: 28608667]
95. Ulubay M, Keskin U, Fidan U, et al. Safety, Efficiency, and Outcomes of Perineoplasty: Treatment of the Sensation of a Wide Vagina. *Biomed Res Int.* 2016;2016:1–5. doi:10.1155/2016/2495105.
96. Vicariotto F, Raichi M. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device. *Minerva Ginecol.* 2016;68(3):225–236. <http://www.ncbi.nlm.nih.gov/pubmed/27206062>. [PubMed: 27206062]
97. Sekiguchi Y, Utsugisawa Y, Azekosi Y, et al. Laxity of the Vaginal Introitus After Childbirth: Nonsurgical Outpatient Procedure for Vaginal Tissue Restoration and Improved Sexual Satisfaction Using Low-Energy Radiofrequency Thermal Therapy. *J Women's Heal.* 2013;22(9):775–781. doi:10.1089/jwh.2012.4123.
98. Millheiser LS, Pauls RN, Herbst SJ, Chen BH. Radiofrequency Treatment of Vaginal Laxity after Vaginal Delivery: Nonsurgical Vaginal Tightening. *J Sex Med.* 2010;7(9):3088–3095. doi: 10.1111/j.1743-6109.2010.01910.x. [PubMed: 20584127]
99. Reed BD, Harlow SD, Sen A, et al. Prevalence and demographic characteristics of vulvodynia in a population-based sample. *Am J Obstet Gynecol.* 2012;206(2):170.e1–9. doi:10.1016/j.ajog.2011.08.012. [PubMed: 21963307]
100. Eppsteiner E, Boardman L, Stockdale CK. Vulvodynia. *Best Pract Res Clin Obstet Gynaecol.* 7 2014. doi:10.1016/j.bpobgyn.2014.07.009.
101. Bornstein J, Goldstein AT, Stockdale CK, et al. 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. *Obstet Gynecol.* 2016;127(4):745–751. doi:10.1097/AOG.0000000000001359. [PubMed: 27008217]
102. ACOG Committee on Gynecologic Practice. ACOG Committee Opinion: Number 345, October 2006: vulvodynia. *Obstet Gynecol.* 2006;108(4):1049–1052. <http://www.ncbi.nlm.nih.gov/pubmed/17012483>. [PubMed: 17012483]
103. Haefner HK, Collins ME, Davis GD, et al. The Vulvodynia Guideline. 2005:1–12.
104. Leclair CM, Goetsch MF, Lee KK, Jensen JT. KTP-nd:YAG laser therapy for the treatment of vestibulodynia: a follow-up study. *J Reprod Med.* 2007;52(1):53–58. <http://www.ncbi.nlm.nih.gov/pubmed/17286070>. [PubMed: 17286070]
105. Lev-Sagie A, Kopitman A, Brzezinski A. Low-Level Laser Therapy for the Treatment of Provoked Vestibulodynia—A Randomized, Placebo-Controlled Pilot Trial. *J Sex Med.* 2017;14(11):1403–1411. doi:10.1016/j.jsxm.2017.09.004. [PubMed: 28970071]

106. Tschanz C, Salomon D, Skaria A, Masouyé I, Vecchiotti GL, Harms M. Vulvodinia after CO<sub>2</sub> Laser Treatment of the Female Genital Mucosa. *Dermatology*. 2001;202(4):371–372. doi: 10.1159/000051686. [PubMed: 11455164]
107. Murphy R Lichen sclerosis. *Dermatol Clin*. 2010;28(4):707–715. doi:10.1016/j.det.2010.07.006. [PubMed: 20883914]
108. Powell JJ, Wojnarowska F. Lichen sclerosis. *Lancet (London, England)*. 1999;353(9166):1777–1783. <http://www.ncbi.nlm.nih.gov/pubmed/10348006>. Accessed April 24, 2017.
109. Bleeker MCG, Visser PJ, Overbeek LIH, van Beurden M, Berkhof J. Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2016;25(8):1224–1230. doi:10.1158/1055-9965.EPI-16-0019. [PubMed: 27257093]
110. Lansdorp CA, Van Den Hondel KE, Korfage IJ, Van Gestel MJ, Van Der Meijden WI. Quality of life in Dutch women with lichen sclerosis. *Br J Dermatol*. 2013;168(4):787–793. doi:10.1111/bjd.12137. [PubMed: 23252667]
111. Preti M, Scurry J, Marchitelli CE, Micheletti L. Vulvar intraepithelial neoplasia. *Best Pract Res Clin Obstet Gynaecol*. 2014;28(7):1051–1062. doi:10.1016/j.bpobgyn.2014.07.010. [PubMed: 25106700]
112. Micheletti L, Preti M, Radici G, et al. Vulvar Lichen Sclerosus and Neoplastic Transformation: A Retrospective Study of 976 Cases. *J Low Genit Tract Dis*. 2016;20(2):180–183. doi:10.1097/LGT.000000000000186. [PubMed: 26882123]
113. Halonen P, Jakobsson M, Heikinheimo O, Riska A, Gissler M, Pukkala E. Lichen sclerosis and risk of cancer. *Int J Cancer*. 2017;140(9):1998–2002. doi:10.1002/ijc.30621. [PubMed: 28124469]
114. Renaud-Vilmer C Vilmer Lichen sclerosis Arch Dematol 2004.pdf. 2004.
115. Lee A, Bradford J, Fischer G. Long-term Management of Adult Vulvar Lichen Sclerosus. *JAMA Dermatology*. 2015;151(10):1061. doi:10.1001/jamadermatol.2015.0643. [PubMed: 26070005]
116. Edwards SK, Bates CM, Lewis F, Sethi G, Grover D. 2014 UK national guideline on the management of vulval conditions. *Int J STD AIDS*. 2015;26(9):611–624. doi: 10.1177/0956462414554271. [PubMed: 25300587]
117. Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosis. *J Eur Acad Dermatol Venereol*. 2015;29(10):e1–43. doi:10.1111/jdv.13136.
118. van der Meijden W, Boffa M, ter Harmsel W, et al. 2016 European guideline for the management of vulval conditions Conflicts of interest. doi:10.1111/jdv.14096.
119. Kreuter PA, Germany O, Aberer PW. Guideline on Lichen sclerosis. 2017.
120. Stuart GCE, Malliah VS R DI. Laser therapy for Vulvar Lichen Sclerosus. *CJS*. 1991;34(5):469–470.
121. Kartamaa M, Reitamo S. Treatment of lichen sclerosis with carbon dioxide laser vaporization. *Br J Dermatol*. 1997;136(3):356–359. [PubMed: 9115915]
122. Peterson CM, Lane JE, Ratz JL. Successful carbon dioxide laser therapy for refractory anogenital lichen sclerosis. *Dermatol Surg*. 2004;30(8):1148–1151. doi:10.1111/j.1524-4725.2004.30343.x. [PubMed: 15274708]
123. Lee A, Lim A, Fischer G. Fractional carbon dioxide laser in recalcitrant vulval lichen sclerosis. *Australas J Dermatol*. 2016. doi:10.1111/ajd.12305.
124. Camargo CM dos S, Brotas AM, Ramos-e-Silva M, Carneiro S. Isomorphic phenomenon of Koebner: Facts and controversies. *Clin Dermatol*. 2013;31(6):741–749. doi:10.1016/j.clindermatol.2013.05.012. [PubMed: 24160280]
125. Marchitelli CE, Sluga MC, Perrotta M, Testa R. Initial Experience in a Vulvovaginal Aesthetic Surgery Unit Within a General Gynecology Department. *J Low Genit Tract Dis*. 2010;14(4):295–300. doi:10.1097/LGT.0b013e3181d8594a. [PubMed: 20885155]
126. Cihantimur B, Herold C. Genital beautification: a concept that offers more than reduction of the labia minora. *Aesthetic Plast Surg*. 2013;37(6):1128–1133. doi:10.1007/s00266-013-0211-4. [PubMed: 24042737]
127. Fadul-Elahi T, Janjua N. Laser-induced synlabia, cryptomenorrhea, and urine retention: A case report and literature review. *Urol Ann*. 2017;9(4):380. doi:10.4103/UA.UA\_7\_17. [PubMed: 29118543]

128. Vieira-Baptista P, Lima-Silva J, Fonseca-Moutinho J, Monteiro V, Águas F. Survey on Aesthetic Vulvovaginal Procedures: What do Portuguese Doctors and Medical Students Think? *Rev Bras Ginecol e Obs / RBGO Gynecol Obstet.* 2017;39(8):415–423. doi:10.1055/s-0037-1603967.
129. No Title. <http://www.drmatlock.com/body-procedures-beverly-hills/laser-vaginal-rejuvenation-with-designer-laser-vaginoplasty-combination/>.
130. Pardo J, Solà V, Ricci P, Guilloff E. Laser labioplasty of labia minora. *Int J Gynecol Obstet.* 2006;93(1):38–43. doi:10.1016/j.ijgo.2006.01.002.
131. Smarrito S Lambda laser nymphoplasty: retrospective study of 231 cases. *Plast Reconstr Surg.* 2014;133(2):231e–2e. doi:10.1097/01.prs.0000437239.53671.6f. [PubMed: 25942278]
132. González-Isaza P, Lotti T, França K, et al. Carbon Dioxide with a New Pulse Profile and Shape: A Perfect Tool to Perform Labioplasty for Functional and Cosmetic Purpose. *Open Access Maced J Med Sci.* 2018;6(1). doi:10.3889/oamjms.2018.043.
133. Vieira-Baptista P, Lima-Silva J, Beires J. «Intimate surgery»: what is done and under which scientific basis? *Acta Obs Ginecol Port.* 2015;9(5):393–399.
134. Emhardt E, Siegel J, Hoffman L. Anatomic variation and orgasm: Could variations in anatomy explain differences in orgasmic success? *Clin Anat.* 2016;29(5):665–672. doi:10.1002/ca.22703. [PubMed: 26916103]
135. Brodie K, Alaniz V, Buyers E, et al. A Study of Adolescent Female Genitalia: What is Normal? *J Pediatr Adolesc Gynecol.* 2019;32(1):27–31. doi:10.1016/j.jpag.2018.09.007. [PubMed: 30244193]
136. Beauchamp TL, Childress JF. *Principles of Biomedical Ethics.* Seventh Ed. Oxford University Press; 2012.
137. DeLeon FD, Baggish MS. Lasers in Gynecology. *Glob Libr Women's Med.* 2009. doi:10.3843/GLOWM.10023.
138. Song S, Budden A, Short A, Nesbitt-Hawes E, Deans R, Abbott J. The evidence for laser treatments to the vulvo-vagina: Making sure we do not repeat past mistakes. *Aust New Zeal J Obstet Gynaecol.* 2018;58(2):148–162. doi:10.1111/ajo.12735.

### Recommendations

Based on the available scientific evidence, with no supporting long term follow-up data, the use of LASER should, at present, not be recommended for the treatment of vaginal atrophy, vulvodynia or lichen sclerosus. The data for the role of LASER for stress urinary incontinence and vaginal laxity are inadequate to draw any conclusions or safe practice recommendations. Therefore based on the available scientific evidence and on the lack of long term follow-up, the use of LASER should, so far, not be recommended for the treatment of vaginal atrophy, vulvodynia, lichen sclerosus, stress urinary incontinence, vaginal prolapse, or vaginal laxity.

**Table 1**

The use of LASER in the vagina for the treatment of atrophy/rejuvenation.

	<b>Level of evidence</b>	<b>Grade of recommendation</b>
The mechanism of action of LASER on vaginal tissue in normal or diseased states is not known and cannot be used to justify treatment results	3b/4	C

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript



**Table 2**

The histology of vaginal LASER “rejuvenation”.

	Level of evidence	Grade of recommendation
The histological changes present after LASER therapy are consistent with reparative changes after a thermal injury. They do not necessarily represent restoration of function, and cannot be used to justify treatment results.	4	C

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript

**Table 3**

Impact on the vaginal microbiome.

	<b>Level of evidence</b>	<b>Grade of recommendation</b>
LASER cannot be recommended as a means to improve the vaginal microbiome.	2b	B
The use of CO <sub>2</sub> LASER does not negatively impact the vaginal microbiome.	2b	B

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript

**Table 4**

“Genitourinary syndrome of menopause” & vaginal atrophy.

	<b>Level of evidence</b>	<b>Grade of recommendation</b>
There is currently not enough scientific data demonstrating efficacy and safety of LASER for treating vulvovaginal atrophy.	2b/3b	C

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript

**Table 5**

Stress urinary incontinence and/or pelvic organ prolapse.

	<b>Level of evidence</b>	<b>Grade of recommendation</b>
There is limited evidence supporting the use of LASER for stress urinary incontinence	4	D
There is limited data concerning the safety of LASER for stress urinary incontinence	4	D
The evidence supporting the use of LASER for pelvic organ prolapse is limited	4	D
The data concerning the safety of LASER for pelvic organ prolapse is limited	4	D

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript

**Table 6**

“Vaginal Laxity Syndrome”.

	<b>Level of evidence</b>	<b>Grade of recommendation</b>
There are no data supporting the recommendation of performing “vaginal rugation rejuvenation” or showing its safety.	4	D
Er: YAG LASER for vaginal looseness or laxity has not been shown to be safe or efficacious	4	D

**Table 7**

Vulvodynia.

	<b>Level of evidence</b>	<b>Grade of recommendation</b>
LASER therapy cannot be recommended as a means to improve pain in vulvodynia.	2b	B
The use of low-level LASER does not negatively impact symptoms in vestibulodynia.	2b	B

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript

**Table 8**

Lichen sclerosus.

	<b>Level of evidence</b>	<b>Grade of recommendation</b>
There are no data supporting the use of CO <sub>2</sub> LASER in VLS	4	C
There are no data concerning the long term safety of the use of CO <sub>2</sub> LASER in VLS treatment	4	C

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript

**Table 9**

Other possible uses of LASER (vulvar bleaching/whitening /brightening, labiaplasty)

	<b>Level of evidence</b>	<b>Grade of recommendation</b>
There is no medical indication for the use of LASER for vulvar bleaching	4	C
There are no data concerning the safety of the use of LASER for vulvar bleaching	4	C
Nd:YAG and CO <sub>2</sub> LASER appear to be safe options for labiaplasty	3b	C
There is no data supporting the use of LASER labiaplasty to enhance sexual function	4	C

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript